Pioglitazone: an anti-diabetic compound with anti-aging properties |
| |
Authors: | Mahtab Jafari Behnood Khodayari Jeffrey Felgner Irvin I Bussel Michael R Rose Laurence D Mueller |
| |
Institution: | (1) Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA;(2) Undergraduate Program, School of Biological Sciences, University of California, Irvine, CA 92697-2525, USA;(3) Department of Ecology and Evolutionary Biology, University of California, Irvine, CA 92697-2525, USA |
| |
Abstract: | Insulin and Insulin-Growth-Factor-like (IGF) signaling pathways are well known longevity pathways in nematodes, insects and
mammals. To our knowledge, there are no systematic pharmacological studies evaluating the anti-aging properties of medications
that target this pathway in Drosophila. Although there are no published data implicating an anti-aging role for these compounds in Drosophila, we hypothesized that their promising pharmacological profile might decrease mortality. However, the decrease in mortality
could be due to a number of potential artifacts and confounds such as fecundity depression, decrease in metabolic rate, or
CNS depression. Therefore, the mere finding that a compound decreases mortality does not qualify it as an anti-aging compound.
In this study, we evaluated the anti-aging properties of four compounds that might target the insulin signaling pathway in
Drosophila. Once it was established that the compound decreased mortality, we proceeded to evaluate possible confounding factors that
could have contributed to the mortality reduction. We show that only piolglitazone displayed anti-aging properties. At present,
we do not have a mechanistic explanation for this pharmacological disparity. |
| |
Keywords: | Anti-aging Anti-diabetics Drosophila Drug testing Lifespan Longevity |
本文献已被 PubMed SpringerLink 等数据库收录! |
|